Novavax announced on July 29 a positive preclinical trial for its virus-like particle vaccine candidate against the H7N9 Influenza A, which protected 100 percent of the mice studied in the trial from infection.
The data from the study was published in the journal Vaccine. Researchers in the study used three control groups to test the efficacy of the new vaccine candidate; the control groups used a VLP vaccine against H7N3, a VLP vaccine against H5N1 and a placebo. Some of the immunizations also contained Isomatrix, an adjuvant based on saponin.
Researchers from the study conducted the preclinical trial based on a mouse model. During the study, researchers saw an increase in the hemagglutination-inhibition antibody response towards H7N9.
No comments:
Post a Comment